🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

29 results for “Darzalex” Clear

  1. POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, DARZALEX 1800 mg solution for injection, DEXAMETHASONE, DEXAMETHASONE

    Wuhan Createrna Science and Technology Co., Ltd

    Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  2. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  3. SOLDESAM 0,2% gocce orali, soluzione, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, SOLDESAM 8 mg/2 ml soluzione iniettabile, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules

    Fondazione Telethon ETS

    Multiple Myeloma relapsed and/or refractory

    phase 2 small molecule active

    1 trial

  4. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  5. teclistamab, JNJ-64407564, JNJ-64407564, teclistamab, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources